Dr. Alan Wu, a professor at UCSF School of Medicine, will moderate the discussion and present on the analytical requirements for TBI biomarker testing. Joining him is Dr. Frank Peacock IV from the Baylor College of Medicine, who will define Acute Traumatic Encephalopathy and share updates on the company-sponsored HeadSmart II clinical trial. This pivotal study, utilizing over 2,000 samples, aims to support a forthcoming FDA regulatory submission for the BRAINBox TBI diagnostic test.
BRAINBox Advisors to Address TBI Biomarker Standards at ADLM Meeting
Two members of the BRAINBox Solutions Scientific Advisory Board will take the stage at the Association for Diagnostics and Laboratory Medicine annual meeting in Anaheim on July 27. The panel focuses on new guidance from the National Institute for Neurological Disorders and Stroke regarding the diagnosis and prognosis of mild traumatic brain injury.
The system integrates proprietary blood biomarkers with neurocognitive assessments, processed via AI to deliver a single-system score for injury severity. BRAINBox Solutions CEO Donna Edmonds noted that the panel appearance highlights the company's role in shifting clinical practice toward objective, AI-integrated risk stratification for concussions.
Comments (0)
No comments yet. Be the first!